AlphaQuest LLC Acquires 7,940 Shares of Novavax, Inc. (NASDAQ:NVAX)

AlphaQuest LLC raised its stake in Novavax, Inc. (NASDAQ:NVAX) by 290.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,677 shares of the biopharmaceutical company’s stock after acquiring an additional 7,940 shares during the period. AlphaQuest LLC’s holdings in Novavax were worth $86,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. Victory Capital Management Inc. lifted its holdings in shares of Novavax by 12.0% during the 3rd quarter. Victory Capital Management Inc. now owns 19,292 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 2,072 shares during the period. Intech Investment Management LLC bought a new position in shares of Novavax in the 3rd quarter valued at $527,000. Massachusetts Financial Services Co. MA raised its holdings in Novavax by 24.2% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 93,457 shares of the biopharmaceutical company’s stock valued at $1,180,000 after buying an additional 18,229 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Novavax by 16.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,325,508 shares of the biopharmaceutical company’s stock worth $16,741,000 after purchasing an additional 187,548 shares during the last quarter. Finally, Bank of Montreal Can raised its position in shares of Novavax by 26.7% during the third quarter. Bank of Montreal Can now owns 2,454,325 shares of the biopharmaceutical company’s stock worth $32,643,000 after acquiring an additional 517,727 shares during the last quarter. 53.04% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

NVAX has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $19.00 price objective on shares of Novavax in a research note on Tuesday, December 10th. TD Cowen raised shares of Novavax to a “hold” rating in a research report on Thursday, February 27th. Finally, BTIG Research began coverage on shares of Novavax in a report on Friday, February 28th. They issued a “buy” rating and a $19.00 price target on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Novavax presently has a consensus rating of “Hold” and an average target price of $18.00.

Insider Transactions at Novavax

In related news, Director James F. Young sold 5,400 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $8.00, for a total transaction of $43,200.00. Following the transaction, the director now directly owns 51,760 shares in the company, valued at $414,080. This trade represents a 9.45 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 1.00% of the company’s stock.

Novavax Trading Down 5.1 %

NVAX stock opened at $7.95 on Wednesday. The firm has a market capitalization of $1.28 billion, a P/E ratio of -3.52, a price-to-earnings-growth ratio of 2.85 and a beta of 2.92. Novavax, Inc. has a 12 month low of $3.81 and a 12 month high of $23.86. The firm has a 50 day moving average of $8.35 and a 200-day moving average of $9.59.

Novavax (NASDAQ:NVAX) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.24. The firm had revenue of $88.31 million for the quarter, compared to analysts’ expectations of $85.48 million. During the same quarter in the previous year, the business earned ($1.44) EPS. Sell-side analysts predict that Novavax, Inc. will post -1.46 EPS for the current year.

Novavax Profile

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.